A Multicenter Prospective Study of Application of Platelet Mapping in Acute-on-chronic-liver Failure in China
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 486
- 试验地点
- 1
- 主要终点
- 28-day mortality
研究概览
简要总结
Ineffective hemostasis or a paradoxical prothrombotic state of Acute-on-chronic liver disease (ACLF) has been well established. Thrombelastography measures the dynamics of thrombin production and provides a global assessment of coagulation incorporating the cumulative effect of the interactions at various levels between plasma components and cellular component of coagulation. And through the platelet mapping, it can help provide a picture of patients' function of platelet. Based on the primary result of our derivation cohort(NCT03281278), ACLF patients with high ADP inhibition rate had high 28-day mortality.This multicenter validation cohort aims to validate the predictive role of platelet mapping in ACLF prognosis, organ failure developments and short term mortality.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 年龄范围
- 18 Years 至 80 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •INR≥1.5 and total bilirubin≥85μmol/L
排除标准
- •INR≤1.5 or total bilirubin≤85μmol/L;
- •those who had hepatocellular carcinoma or other types of malignancies;
- •obstructive biliary diseases or other disease lead to bilirubin evaluation;
- •those who had acute hemorrhage one week before admission
- •those who received platelet, cryo transfusion or plasmapheresis one week before admission
- •pregnancy and breastfeeding
- •those who received liver transplantation or kidney transplantation;
- •combine with other disease lead to organ failure including heart failure (NYHA IV),respiratory failure（PaO2<60mmHg),renal insufficiency(CKD 5) and conscious disturbance (GCS<8)
- •readmission;
- •death within 24 hours.
结局指标
主要结局
28-day mortality
时间窗: 28-day
death within 28-day
次要结局
- 28-day progression(28-day)
- 90-day mortality(90-day)